When Ark Invest (ARK) sold a substantial stake in Palantir (PLTR), it proved too early. PLTR stock continued to rise to an ...

EDP-323 is an investigational inhibitor of Respiratory Syncytial Virus (RSV), currently showing promising results in Phase 2a ...

The prescription-free test you can take at home will help discern which respiratory virus you have, as symptoms often overlap ...

Thursday reported positive topline results from the Phase 3 TALAPRO-2 study of Talzenna in combination with Xtandi ...

The CDC recommends getting an updated 2024-2025 COVID-19 vaccine to protect against potentially serious illness associated with the latest variants of the virus, noting that protection from vaccines ...

You can find plenty of affordable stocks that offer solid long-term growth prospects. If you're interested in the healthcare ...

Authorizing Medicare to cover weight loss drugs would increase federal spending by about $35 billion from 2026 to 2034 ...

Pfizer to present data across respiratory and other infectious diseases portfolio at IDWeek 2024 congress: New York Thursday, October 10, 2024, 09:00 Hrs [IST] Pfizer Inc. will pr ...

Bourla and Shantanu Narayen, Pfizer's lead independent director and Adobe Systems CEO, will hold talks with Starboard chief ...

Results from the REVISIT trial show aztreonam-avibactam had similar cure rates as meropenem in patients with serious ...

The protection also held across different strains, for people in their 70s, and for those with underlying medical conditions.